Lipoprotein (A) As a Predictor of Diabetic Retinopathy in Patients With Type 2 Diabetes: A Systematic Review Publisher Pubmed



Gholami Chahkand MS¹ ; Esmaeilpour Moallem F² ; Qezelgachi A³ ; Seifouri K⁴ ; Pesaran Afsharian A⁵ ; Sheikhzadeh F⁶ ; Poursalehi A⁷ ; Fani Sadrabadi FS⁸ ; Saghab Torbati M⁹ ; Ramezanzade M¹⁰ ; Alishiri G¹¹ ; Ansari A¹² ; Zare Dehabadi E⁴ ; Karimi Matloub S¹³ Show All Authors
Source: Diabetes and Vascular Disease Research Published:2023

Abstract

Background: Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes—the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy. Methods: A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention. Result: 17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy. Conclusion: High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding. © The Author(s) 2023.